On the latest episode of The Cannabis Conversation, we speak with Dr. Franjo Grotenhermen, Chairperson at the International Association of Cannabinoid Medicines (IACM).

We explore his journey into cannabis medicine, its diverse uses, and the challenges of its regulation. Together, we look at the importance of patient experiences and the need for a balance between clinical trials and real-world experiences. We also examine the risk profile of cannabis, potential side effects, contraindications, and interactions with other medications. 

The Cannabis Conversation is sponsored by Lumino - a boutique HR and Recruitment Agency specialising in building high performance teams for the European Cannabis Industry. They work in three main verticals: Commercial, Medical and Plant Facing.

Get in touch at www.luminorecruit.com/

About Franjo Grotenhermen M.D.

Franjo Grotenhermen graduated in medicine and received his doctorate in Cologne. His fields of practice included internal medicine, surgery and naturopathy. He is head of the Centre for Cannabis Medicine in Steinheim (NRW) with a focus on therapy with cannabis and cannabinoids. Grotenhermen is Executive Director of the Arbeitsgemeinschaft Cannabis als Medizin e.V. (ACM) (since 1997), Executive Director of the International Alliance for Cannabinoid Medicines (IACM) (since 2000) and author of the IACM-Bulletin, which is published fortnightly in several languages on the IACM website.

Grotenhermen is an employee of the Cologne-based nova Institute, co-owner of Endoxo GmbH (founded in 2019), a company that produces CBD and other hemp products. He is a lecturer at Dresden International University. He is Chief Medical Advisor of canncura, an internet platform for telemedicine in the field of cannabis and cannabinoids. He is a member of the Scientific Advisory Board of the journals Cannabis and Cannabinoid Research, edited by Prof. Daniele Piomelli at Mary Ann Liebert Publishing. He received the following awards: Hanf-Preis 1999 of Cannabusiness, IACM 2011 Special Award, ICBC 2018 Lifetime Achievement Award, Robert Newman Memorial Award 2018 of Akzept e.V., Honorary Award GFS-Award 2021 of Gemeinnützige Forschungsvereinigung Saluplanta e.V.

Resources

Connect with Franjo on LinkedIn: linkedin.com/in/franjo-grotenhermen-65624b19b

IACM’s Website: https://cannabis-med.org/

On the latest episode of The Cannabis Conversation, we speak with William Muecke of Artemis Growth Partners & Daniel Grözinger of Park Lane Capital.

We look at the European Cannabis Industry from an investment perspective, including the benefits of the legal cannabis market in Germany and France, the potential for mergers and acquisitions in Europe, and Will and Daniel’s thoughts on what’s needed to succeed in this sector in the next few years.

The Cannabis Conversation is sponsored by Lumino - a boutique HR and Recruitment Agency specialising in building high performance teams for the European Cannabis Industry. They work in three main verticals: Commercial, Medical and Plant Facing.

Get in touch at www.luminorecruit.com/


About William Muecke

Will Muecke is the Managing Member at Artemis Growth Partners, a private equity firm with $390 million in assets, specializing in ESG and impact investments within the global cannabis industry.

He also co-founded CoreCo Private Equity, an ESG-focused fund, recognized as a "Best for the World" fund in 2017, with backing from institutions like the IFC/World Bank and European family offices.

Previously, he served as global co-head of healthcare services at Goldman, Sachs & Co. in New York, with extensive networks across Europe, the United States, and Latin America. 

Currently, he holds the position of Chief Investment Officer at Artemis Growth Partners in London.

About Daniel Grözinger

Daniel Grözinger, a Partner at Parklane Capital in Germany, is a seasoned M&A expert with a focus on the tech sector. In 2021, he expanded his expertise into the cannabis market and played a pivotal role in the sale of Four 20 Pharma to Curaleaf in 2022.

With a background in over 75 M&A deals, Daniel is also a serial entrepreneur. Notably, he co-founded getgo.de, an online ticketing industry leader, and sold it to CTS Eventim AG. He then managed two business units at CTS, generating over 500 million EUR in revenue.

In 2003, he founded uniquedigital, a top-ranked online marketing agency, later acquired by Syzygy AG in 2008. Daniel has a history of founding and building customer-focused companies, including verwandt.de, Farbflut Entertainment, Emporis, and Animod, among others. He has also invested in various internet companies and startups as a business angel, including Prezi.com and Fiverr, before joining Parklane Capital in 2014.

Resources

Connect with William on LinkedIn: https://www.linkedin.com/in/wmuecke

Connect with Daniel on LinkedIn: https://www.linkedin.com/in/groezinger/

Artemis Growth Partners’ Website: www.artemisgrowth.com

Parklane Capital’s Website: 

On the latest episode of The Cannabis Conversation, we’re joined by Mike Roberts, a medical cannabis patient in the UK. 

We explore Mike’s journey with cannabis, the potential benefits of incorporating cannabis into cancer treatment plans, and his trailblazing story of becoming the first patient to successfully get his cannabis flower prescription reimbursed by the NHS.

The Cannabis Conversation is sponsored by Lumino - a boutique HR and Recruitment Agency specialising in building high performance teams for the European Cannabis Industry. They work in three main verticals: Commercial, Medical and Plant Facing.

Get in touch at www.luminorecruit.com/

About Mike Roberts

Mike Roberts is a special needs teacher, musician, and father. His interests include photography, chemistry, and medical cannabis. In 2021 at the age of 43, Mike was diagnosed with incurable cancer. In 2023 he became the first person in the UK to receive NHS funding for cannabis flower.

Resources

Connect with Mike on LinkedIn: https://www.linkedin.com/in/mike-roberts-42a46122b

Mike’s Website: https://www.michaelrobertstutoring.com/